Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4 ...

The company has approved medicines that treat the underlying causes of multiple chronic ... sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical ...

Detroit — The Detroit Medical Center has begun treating patients with the first gene therapy for beta-thalassemia, a rare blood disorder that causes anemia and often requires regular blood ...

was diagnosed with Beta Thalassemia Major. He has been on monthly blood transfusions since he was six months old. Thalassemia Major is a severe, inherited blood disorder that causes low levels of ...

While rare in Britain, the genetic disorder places a major burden on healthcare systems in countries like Thailand and Laos ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conferenc ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

If the most serious form of alpha thalassemia (which causes stillbirth) is found, an abortion is immediately carried out; if another form such as beta thalassemia is diagnosed (which requires ...

In that spirit, let's discuss two companies that meet those criteria: HCA Healthcare ( HCA 2.23%) and Vertex Pharmaceuticals ( VRTX -3.15%). Here's why their stocks could deliver better returns than ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on ...